<div class="docx-content">
<p><strong>BASHH STI Revision Notes</strong></p><p>Last updated: 23 July 2025</p><p><strong>Contents</strong></p><ol><li>Chlamydia trachomatis – 2015 BASHH guideline</li><li>Lymphogranuloma Venereum (LGV) – 2013 BASHH guideline</li></ol><p><strong>1 Chlamydia trachomatis (2015)</strong></p><p><strong>1.1 Scope &amp; Key Updates</strong></p><ul><li>Adults ≥ 16 y attending UK level‑3 sexual‑health services; principles adapt elsewhere.</li><li>2015 revision: universal NAAT use, emerging NAAT‑POCT, repeat‑testing rules, rectal infection guidance, azithro vs doxy debate, pregnancy/neonate advice.</li></ul><p><strong>1.2 Epidemiology &amp; Aetiology</strong></p><ul><li>Most common curable STI in UK – &gt; 208 000 diagnoses (2013); 70 % aged 15–24.</li><li>Prevalence 1.5–4.3 % in population surveys; risk ↑ in &lt; 25 y, new/multiple partners, inconsistent condoms.</li><li>Serovars D–K cause urogenital, L1–L3 cause LGV; ~75 % partner concordance; up to half clear spontaneously in 12 m.</li></ul><p><strong>1.3 Clinical Presentation (summary)</strong></p><ul><li>Women: discharge, IMB/PCB, dysuria, pelvic pain → mucopurulent cervicitis, PID, infertility, ectopic, perihepatitis, SARA.</li><li>Men: mild urethral discharge/dysuria → epididymo‑orchitis, SARA.</li><li>Rectum: mostly asymptomatic; may discharge/tenesmus; can mimic proctitis.</li><li>Pharynx / Conjunctiva: usually silent; chronic unilateral conjunctivitis possible.</li></ul><p><strong>1.4 Diagnosis</strong></p><p><strong>Preferred Assay</strong></p><ul><li>First‑line NAATs – genital &amp; extra‑genital; dual‑platform confirmation only for medico‑legal cases.</li></ul><p><strong>Optimal Specimens</strong></p><table><thead><tr><th><p><strong>Group</strong></p></th><th><p><strong>Best specimen</strong></p></th></tr></thead><tbody><tr><td><p>Women</p></td><td><p>Self‑ or clinician‑taken vulvo‑vaginal swab (VVS) – highest sensitivity</p></td></tr><tr><td><p>Men</p></td><td><p>First‑catch urine (FCU) ≈ urethral swab</p></td></tr><tr><td><p>Rectal / Pharyngeal</p></td><td><p>Site‑specific swab for NAAT</p></td></tr><tr><td><p>LGV screen</p></td><td><p>Send CT‑positive samples to STBRL for LGV PCR</p></td></tr></tbody></table><p><strong>Practical Points</strong></p><ul><li>If exposure &lt; 14 d: test now and repeat ≥ 2 wks.</li><li>Self‑sampling (vaginal, rectal, pharyngeal) is acceptable &amp; accurate – supports home testing.</li><li>nvCT deletion resolved in modern assays.</li><li>Medico‑legal cases: sample all penetrated sites, confirm positives on a second NAAT target.</li></ul><p><strong>1.5 Management</strong></p><p><strong>General Measures</strong></p><ul><li>STI screen incl. HIV, syphilis, gonorrhoea; vaccinate/test for HBV.</li><li>Abstain from sexual contact until both partners treated and 7 d have passed since azithro or completion of doxy.</li><li>Do not remove IUD/IUS for uncomplicated CT.</li><li>Provide written info, safer‑sex and partner‑notification counselling.</li></ul><p><strong>Recommended Regimens</strong></p><table><thead><tr><th><p><strong>Scenario</strong></p></th><th><p><strong>First‑line</strong></p></th><th><p><strong>Alternatives / notes</strong></p></th></tr></thead><tbody><tr><td><p>Uncomplicated genital / pharyngeal CT</p></td><td><p>Doxycycline 100 mg BD × 7 d or Azithromycin 1 g stat</p></td><td><p>Ofloxacin 200 mg BD 7 d; erythro 500 mg BD 10–14 d</p></td></tr><tr><td><p>Rectal CT (non‑LGV)</p></td><td><p>Doxy 100 mg BD 7 d</p></td><td><p>Azithro 1 g stat with TOC or longer doxy if LGV not excluded</p></td></tr><tr><td><p>Pregnancy / breast‑feeding</p></td><td><p>Azithro 1 g stat</p></td><td><p>Erythro 500 mg QDS 7 d, BD 14 d, or Amox 500 mg TDS 7 d</p></td></tr><tr><td><p>CT + Gonorrhoea</p></td><td><p>Standard GC Rx (ceftriaxone 500 mg IM + azithro 1 g) covers CT; add doxy 7–21 d if rectal CT/LGV risk</p></td><td></td></tr><tr><td><p>HIV‑positive</p></td><td><p>Same regimens; err on doxy 3 wks for rectal CT pending LGV PCR</p></td><td></td></tr></tbody></table><p><strong>Adverse‑Effect Pearls</strong></p><ul><li>Doxy: GI upset, photosensitivity, oesophagitis – take with water &amp; stay upright.</li><li>Azithro: GI upset, potential QT prolongation.</li><li>Erythro: marked GI intolerance; avoid in cholestasis.</li></ul><p><strong>1.6 Test of Cure (TOC) &amp; Retesting</strong></p><ul><li>Routine TOC not required – except pregnancy, suspected non‑adherence, persistent symptoms, rectal CT treated with azithro, or LGV not excluded.</li><li>If done, sample ≥ 3 wks post‑therapy to avoid residual DNA.</li><li>Repeat screen at 3 months for all positives &lt; 25 y (high reinfection risk).</li></ul><p><strong>1.7 Partner Notification</strong></p><ul><li>Look‑back:<ul><li>Symptomatic men (urethritis): partners since, plus 4 wks before onset.</li><li>All others: partners in previous 6 m.</li></ul></li><li>Offer epidemiological treatment to all contacts.</li><li>Auditable standard: ≥ 97 % have documented partner‑action plan &amp; correct SHHAPT coding.</li></ul><p><strong>1.8 Pregnancy &amp; Neonate</strong></p><ul><li>Vertical transmission → conjunctivitis (5–12 d) or pneumonia (1–3 m).</li><li>Treat infant: Erythro 50 mg/kg/day PO ÷ 4 × 14 d.</li><li>Test &amp; treat mother and partners; perform maternal TOC ≥ 3 wks post‑therapy.</li></ul><p><strong>1.9 Point‑of‑Care Testing</strong></p><ul><li>Older EIAs insensitive; new NAAT‑POCTs deliver comparable accuracy within &lt; 2 h but extra‑genital validation ongoing.</li></ul><p><strong>1.10 Exam Take‑Home Messages</strong></p><ol><li>Doxy 7 d vs azithro 1 g – equal for genital CT; doxy better for rectal disease.</li><li>Vulvo‑vaginal swab outscores urine in women.</li><li>Always consider LGV in rectal CT, especially MSM/HIV‑positive – send to STBRL.</li><li>No routine TOC; if required, wait ≥ 3 wks.</li><li>Retest at 3 mths (&lt; 25 y).</li><li>Azithro single‑dose safe in pregnancy; avoid tetracyclines/quinolones.</li><li>97 % documentation of partner plan &amp; coding is a BASHH KPI.</li></ol><p><strong>2 Lymphogranuloma Venereum (LGV) – 2013</strong></p><p><strong>2.1 Scope &amp; What’s New</strong></p><ul><li>Adults ≥ 16 y; UK level‑3 services.</li><li>LGV now hyper‑endemic in UK MSM networks – majority HIV‑positive; serovar L2b dominates.</li><li>Doxy 100 mg BD 21 d remains gold‑standard.</li></ul><p><strong>2.2 Epidemiology &amp; Risk Factors</strong></p><ul><li>77 % of UK cases in London, Brighton, Manchester; sex‑party &amp; chemsex scenes, HCV co‑infection common.</li></ul><p><strong>2.3 Natural History &amp; Clinical Presentation</strong></p><table><thead><tr><th><p><strong>Stage</strong></p></th><th><p><strong>Typical findings</strong></p></th></tr></thead><tbody><tr><td><p>Primary</p></td><td><p>Small transient genital/anal ulcer – often unnoticed</p></td></tr><tr><td><p>Secondary (inguinal / anorectal)</p></td><td><p>Painful bilateral inguinal nodes (buboes) or proctocolitis with bleeding, tenesmus, systemic upset; reactive arthritis possible</p></td></tr><tr><td><p>Tertiary</p></td><td><p>Fibrosis, strictures, fistulae, genital lymphoedema; now rare in outbreak era</p></td></tr></tbody></table><p>Rectal swab microscopy &gt; 10–20 PMNL/HPF strongly predicts LGV in HIV‑positive MSM.</p><p><strong>2.4 Investigations &amp; Diagnosis</strong></p><ul><li>Step 1 – Standard CT NAAT on ulcer exudate, bubo aspirate (through healthy skin), rectal/pharyngeal swab or FCU.</li><li>Step 2 – LGV‑specific PCR confirmation at STBRL (required for definitive diagnosis).</li><li>Additional tests: culture/NAAT for HSV &amp; N. gonorrhoeae, syphilis serology, consider biopsy if malignancy.</li><li>Serology (micro‑IF IgG &gt; 1:128 or anti‑MOMP IgA) supports late disease but not sensitive early.</li></ul><p><strong>2.5 Management</strong></p><p><strong>Recommended Regimens</strong></p><table><thead><tr><th><p><strong>Scenario</strong></p></th><th><p><strong>First‑line</strong></p></th><th><p><strong>Alternatives / notes</strong></p></th></tr></thead><tbody><tr><td><p>All uncomplicated LGV</p></td><td><p>Doxycycline 100 mg BD × 21 d</p></td><td><p>Azithro 1 g weekly × 3 wk; erythro 500 mg QDS 21 d; tetracycline 2 g/day; minocycline 300 mg LD then 200 mg BD (specialist)</p></td></tr><tr><td><p>Pregnancy / tetracycline allergy</p></td><td><p>Erythro 500 mg QDS 21 d with mandatory TOC; extended‑course azithro if intolerant</p></td><td></td></tr><tr><td><p>HIV‑positive</p></td><td><p>Same regimens; no relevant ART interactions</p></td><td></td></tr></tbody></table><p>Fluctuant buboes → aspirate; avoid incision/drainage.</p><p><strong>Adverse‑Effect &amp; Interaction Notes</strong></p><ul><li>Doxy – as per CT.</li><li>Erythro – GI intolerance.</li><li>No clinically significant interactions with standard antiretrovirals.</li></ul><p><strong>2.6 Follow‑up &amp; Test of Cure</strong></p><ul><li>Symptoms usually settle within 1–2 wk (may take 3–6 wk chronic).</li><li>Routine NAAT TOC not required after fully‑adherent 21‑d doxy; if done, wait ≥ 2 wk post‑course.</li><li>Confirm partner‑notification completion; repeat HIV, HCV, syphilis tests after window periods.</li></ul><p><strong>2.7 Chronic/Tertiary Disease Management</strong></p><ul><li>Fibrosis, fistulae, strictures, genital lymphoedema require surgical referral – antibiotics ineffective.</li></ul><p><strong>2.8 Patient Counselling &amp; General Advice</strong></p><ul><li>Emphasise LGV is invasive but fully curable if treated early; untreated may cause permanent damage.</li><li>Abstain from unprotected sex until all partners have completed therapy and follow‑up.</li><li>Provide written information; discuss risk reduction for HIV/HCV (condoms, glove‑use, separate douching equipment, chemsex harms).</li><li>Flag abnormal LFTs in HIV‑positive MSM – trigger HCV‑RNA testing (seroconversion delay).</li></ul><p><strong>2.9 Partner Management &amp; Public‑Health Measures</strong></p><ul><li>Look‑back period:<ul><li>Symptomatic index – partners in 4 wk before onset.</li><li>Asymptomatic index – partners in last 3 m.</li></ul></li><li>Offer presumptive doxy 100 mg BD 21 d (or equivalent) to all contacts.</li><li>Auditable 97 % standards: partner‑action plan, serovar confirmation, SHHAPT “C2” coding, repeat BBV testing plan.</li></ul><p><strong>2.10 Exam Take‑Home Messages</strong></p><ol><li>Proctitis in MSM → think LGV; send CT‑positive rectal swab for LGV PCR.</li><li>Diagnosis is two‑step (CT NAAT + LGV‑specific PCR).</li><li>21‑day doxy is gold‑standard; any shorter regimen needs justification + TOC.</li><li>Partner look‑back: 4 wk symptomatic / 3 m asymptomatic.</li><li>Routine TOC only when alternative regimen, pregnancy, poor adherence or persistent symptoms.</li><li>Rectal PMNL &gt; 10–20/HPF is a useful pointer.</li><li>Remember auditable 97 % KPIs, patient counselling and chronic‑stage surgical referral.</li></ol><p>Rapid‑review tip: for essays/vivas, pair each guideline’s “clinical pathway” (diagnosis → treatment → follow‑up → PN → audit) with key numbers (dose, duration, time‑windows, 97 %) to score precision marks.</p>
</div>